Navigation Links
Type of breast reconstruction impacts radiation therapy outcomes
Date:11/20/2008

For breast cancer patients who underwent a mastectomy who undergo radiation therapy after immediate breast reconstruction, autologous tissue reconstruction provides fewer long-term complications and better cosmetic results than tissue expander and implant reconstruction, according to a study in the November issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

After undergoing a mastectomy (surgical removal of the breast), many women choose to have a breast reconstruction procedure performed immediately to better cope with the psychological and esthetic side effects of the surgery. However, the reconstruction can complicate radiation therapy treatments and sometimes radiation can negatively affect the outcome of reconstruction and increase the risk of long-term complications.

With radiation therapy increasingly becoming the standard of care for high-risk breast cancer patients after mastectomy, this can cause a problem for both patients and their radiation oncologists.

Researchers at the Department of Radiation Oncology at Long Island Radiation Therapy in Garden City, N.Y., the Department of Surgery at Long Island Jewish Hospital in New Hyde Park, N.Y., the Department of Surgery at North Shore University Hospital in Manhasset, N.Y., and the Department of Surgery at Winthrop University Hospital in Mineola, N.Y., sought to determine if the type of reconstruction performed on women who were receiving radiation after a mastectomy had an impact on their long-term outcomes.

Two types of reconstruction are available for patients undergoing mastectomy for breast cancer: ATR (autologous tissue reconstruction), which involves the placement of a tissue flap most commonly from the transverse rectus abdominus muscle as a breast mound, and TE/I (tissue expander and implant reconstruction), which involves placing an inflatable tissue expander over the chest wall and exchanging it for a permanent implant at a later date.

This study involved the largest reported series of patients who sequentially underwent mastectomy, immediate reconstruction and postmastectomy radiation therapy. Ninety-two patients were observed for 38 months following their reconstruction and radiation treatments, and researchers found that ATR is better tolerated by breast cancer patients because it is associated with fewer long-term complications and better cosmetic results than TE/I.

None of the 23 ATR patients required surgical intervention, while 33 percent of TE/I patients needed surgery to correct a problem with their reconstruction. Eighty-three percent of ATR patients reported acceptable cosmetic outcome, as opposed to only 54 percent of TE/I patients.

"This study is useful for patients who are candidates for either ATR or TE/I and are making a decision with regards to reconstruction technique," Jigna Jhaveri, M.D., lead author of the study and a radiation oncologist at Advanced Radiation Centers of New York in Hauppauge, N.Y., said. "Our study provides evidence that patients who undergo autologous tissue reconstruction and radiation therapy have fewer long term complications and better cosmetic outcomes than those who undergo tissue expander/ implant reconstruction and radiation therapy."


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Therapeutic Radiology and Oncology
Source:Eurekalert

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... designed to recognize elevated anxiety levels in people with addiction who are served ... Smart Patch, a biosensing wearable device that monitors heart and breath rates to ...
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often perform the ... for lab operators and management to assess these processes with a critical eye—particularly ... unnecessary actions. , Created with the help of both internal and external ...
(Date:4/24/2017)... ... ... “The Saint with Trin, and Omega Station”: a triple feature offering nonstop action ... author, Chris Jackson. Chris Jackson grew up in Abilene, Texas. He now ... teaching English. He is heavily involved in the youth group of his local church. ...
(Date:4/24/2017)... ... , ... A 2-in-1 bottleless water appliance provides both purified ... Texas, here are the ways in which this technology can benefit dental offices: ... fresh, oxygenated water, with both cold and hot options. , Convenience for Dentists ...
(Date:4/22/2017)... NY (PRWEB) , ... April 22, 2017 , ... ... which shows that U.S. consumers can save an average of 70% when buying ... savings (up to 97%) are available when purchasing from other countries. The report ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... SAN DIEGO , April 19, 2017 /PRNewswire/ ... ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new ... today announced the closing of its previously announced ... common stock at a public offering price of ... commissions and estimated offering expenses payable by Sorrento.  ...
Breaking Medicine Technology: